Governor Signs Ibogaine Treatment Research into Law

Translate to Spanish or other 102 languages!

Governor Greg Abbott signed Senate Bill 2308 into law to grant state matching funds for research of ibogaine as an emerging treatment for neurological and mental health conditions during a bill signing ceremony at the Texas Capitol. Photo: Office of The Governor
Governor Greg Abbott signed Senate Bill 2308 into law to grant state matching funds for research of ibogaine as an emerging treatment for neurological and mental health conditions during a bill signing ceremony at the Texas Capitol. Photo: Office of The Governor
- Advertisement -

AUSTIN — Governor Greg Abbott signed Senate Bill 2308 into law to grant state matching funds for research of ibogaine as an emerging treatment for neurological and mental health conditions during a bill signing ceremony at the Texas Capitol. 

“Texas is home to more veterans than any other state,” said Governor Abbott. “Many of those veterans suffer from injuries both seen and unseen. A therapy that has shown great promise in treating those conditions is ibogaine. This law authorizes a Food and Drug Administration approved clinical drug trial that will seek approval of ibogaine as a medication for the treatment of opioid use disorder and other behavioral health conditions, especially those suffered by our veterans. Texas will now lead the way in America for the evaluation of ibogaine as a potential medication that can help improve the lives of so many veterans.” 

View the Governor’s full bill signing ceremony here.

- Advertisement -

The Governor was joined at the bill signing ceremony by Speaker Dustin Burrows, Senator Tan Parker, Senator Charles Perry, and dozens of Texas supporters.

Ibogaine is a plant-based, psychoactive substance that can help treat opioid use disorder, depression, and post-traumatic stress disorder. Senate Bill 2308 allows the Texas Health and Human Services Commission to provide state matching funds for a Food and Drug Administration drug trial managed by a public university in partnership with a drug company and hospital.

Senate Bill 2308 (Parker/Harris) authorizes clinical drug trials on ibogaine to research the potential for treatment of opioid use disorder, depression, and post-traumatic stress disorder.

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

Annual ‘Chalk the Walk’ Event Inspires Connection

Approximately 2.2 million Americans attempted suicide in 2024, according to the American Foundation for Suicide Prevention, while nearly 50,000 lives were lost to suicide. 

DHR Health’s Free Seminar on Breakthrough Treatment for Stroke Survivors, Sept. 19th

DHR Health’s Neuroscience Institute will host a free seminar for stroke survivors who want improved hand and arm movement as many stroke survivors experience impaired mobility and loss of function in the arm which can significantly affect their ability to   perform everyday activities.

STHS Heart’s Intensive Cardiac Rehab Program Earns AACVPR Recertification

Each year, more than 800,000 people in the United States experience a heart attack, according to the American Heart Association, and approximately one in four of those events are repeat occurrence

Newly Discovered Genetic Eye Disease Triggers Night Blindness and Tunnel Vision

Scientists identified a new vision condition linked to a gene already connected to a different vision-loss disease. While the previously identified disease causes loss of central vision, the new condition affects peripheral and night vision.
- Advertisement -